Lipid Levels and Short-Term Risk of Recurrent Brain Infarcts in Symptomatic Intracranial Stenosis

Author(s):  
Shyam Prabhakaran ◽  
David S. Liebeskind ◽  
George Cotsonis ◽  
Azhar Nizam ◽  
Edward Feldmann ◽  
...  
1997 ◽  
Vol 134 (1-2) ◽  
pp. 120
Author(s):  
H. Schrott ◽  
M. Davila ◽  
D.M. Black

2021 ◽  
Vol 15 (Supplement_1) ◽  
pp. S322-S323
Author(s):  
J A M Sleutjes ◽  
J E Roeters van Lennep ◽  
E Boersma ◽  
A C de Vries ◽  
C J van der Woude

Abstract Background Increases of lipid levels associated with inflammatory bowel disease (IBD) medication have been previously reported. However, it is unknown whether this effect is similar for all IBD drug classes. Methods We performed a systematic literature search of randomized controlled trials and observational cohort studies of IBD treatment with corticosteroids, anti TNFα agents and tofacitinib that assessed total cholesterol (TC) before and after short-term (≤8 week) and long-term (≥12 week) treatment. Data of 11 studies (1,663 IBD patients) were pooled using a random effect model with as primary outcome TC levels. Lipid changes were reported as mean difference on the log2-scale (MDlog2) with 95% CI. The effect of patient and disease characteristics on TC changes were analyzed in 6 studies with individual patient data of 1,211 patients. Results A significant increase in TC was observed after treatment with corticosteroids, anti TNFα agents and tofacitinib (short-term +0.370, +0.197 and +0.190; long-term: +0.452, +0.068 and +0.162, respectively). (Figure 1) After correcting for age, sex, BMI and CRP, increases of TC levels after start of corticosteroids and tofacitinib treatment were higher (short-term: +0.293 and +0.161; long-term: +0.090 and +0.127, respectively) as compared to anti TNFα agents (short-term: -0.059, long-term: +0.041). (Figure 2) Conclusion Changes in lipid levels differ between IBD drug classes. TC levels increase was strongest for corticosteroids followed by tofacitinib but not observed for anti TNFα agents. Whether TC change associated with IBD treatment has effect on CVD risk requires further study.


2021 ◽  
Vol 8 ◽  
Author(s):  
Li-Ling Guo ◽  
Yan-qiao Chen ◽  
Qiu-zhen Lin ◽  
Feng Tian ◽  
Qun-Yan Xiang ◽  
...  

This study aimed to compare the percentage attainment of fasting and non-fasting LDL-C and non-HDL-C target levels in coronary heart disease (CHD) patients receiving short-term statin therapy. This study enrolled 397 inpatients with CHD. Of these, 197 patients took statins for <1 month (m) or did not take any statin before admission (CHD1 group), while 204 patients took statins for ≥1 m before admission (CHD2 group). Blood lipid levels were measured at 0, 2, and 4 h after a daily breakfast. Non-fasting LDL-C and non-HDL-C levels significantly decreased after a daily meal (P < 0.05). Both fasting and non-fasting LDL-C or non-HDL-C levels were significantly lower in the CHD2 group. The percentage attainment of LDL-C <1.4 mmol/L at 2 and 4 h after a daily breakfast was significantly higher than that during fasting (P < 0.05), but the percent attainment of non-fasting non-HDL-C <2.2 mmol/L was close to its fasting value (P > 0.05). Analysis of c-statistic showed that non-fasting cut-off points for LDL-C and non-HDL-C were 1.19 and 2.11 mmol/L, corresponding to their fasting goal levels of 1.4 and 2.2 mmol/L, respectively. When post-prandial LDL-C and non-HDL-C goal attainments were re-evaluated using non-fasting cut-off points, there were no significant differences in percentage attainment between fasting and non-fasting states. Non-HDL-C is more stable than LDL-C in assessing the percent attainment of non-fasting lipid for coronary heart disease patients. If we want to use LDL-C to assess the percent attainment of post-prandial blood lipids, we may need to determine a lower non-fasting cut-off point.


1979 ◽  
Vol 13 (2) ◽  
pp. 67-68 ◽  
Author(s):  
O. Bassir ◽  
T. C. Alozie

Summary Aflatoxin B1 significantly depressed serum lipid levels in specimens of Cercopithecus aethiops, Cercopithecus mona, Erythrocebus patas and Papio enubis. Serum cholesterol, total phospholipids and total lipids were not affected to the same extent.


2019 ◽  
Vol 16 (1) ◽  
Author(s):  
Kerry S. Flannagan ◽  
Lindsey A. Sjaarda ◽  
Micah J. Hill ◽  
Matthew T. Connell ◽  
Jessica R. Zolton ◽  
...  

1990 ◽  
Vol 30 (S2) ◽  
pp. S124-S131 ◽  
Author(s):  
Tomas Lindén ◽  
Germán Camejo ◽  
Olov Wiklund ◽  
Ingrid Warnold ◽  
Sven-Olof Olofsson ◽  
...  

Herz ◽  
2019 ◽  
Vol 45 (4) ◽  
pp. 382-388 ◽  
Author(s):  
N. S. Yelgeç ◽  
A. Emre

Sign in / Sign up

Export Citation Format

Share Document